The 2228.HK stock trades at HK$9.91 intraday on 10 Mar 2026 on the HKSE, down 1.49% from yesterday. Volume is 25,682,300 shares, below the 50-day average price but above short-term flows. Investors watching AI-driven drug discovery firms should note XtalPi Holdings Ltd (2228.HK) mixes solid cash buffers with volatile revenue metrics. We examine valuation, technicals, Meyka AI forecasts, and sector context for a clear trading view.
2228.HK stock: Market snapshot and intraday moves
XtalPi Holdings (2228.HK) opened at HK$9.90 and traded between HK$9.77 and HK$10.08 today on HKSE. Market cap stands near HK$41.91B with 4,303,371,761 shares outstanding and average daily volume 69,314,860. Short-term momentum is negative, and price sits below the 50-day average of HK$11.38 but above the 200-day average of HK$9.50.
Fundamentals and valuation for 2228.HK stock
Reported EPS is 1.05 and reported P/E shows 9.28, though TTM metrics reflect mixed margins and high price-to-sales ratios. Key ratios: price/book 4.63, price/sales 54.35, and current ratio 9.69. Cash per share is 0.92 HKD and working capital is robust, but free cash flow per share is negative at -0.13 HKD, showing operational cash burn.
Technicals and trading signals for 2228.HK stock
Momentum indicators show RSI 34.27, MACD histogram -0.10, and ADX 30.85, indicating a strong downward trend with oversold conditions. Bollinger Bands narrow around middle HK$10.64, with lower band at HK$9.26, highlighting intraday support. Traders may watch a break above HK$11.38 for short-covering and below HK$9.26 for trend continuation.
Sector context and peers for 2228.HK stock
XtalPi sits in Healthcare, Medical – Healthcare Information Services on the Hong Kong market. The healthcare sector average P/E is near 27.26, making XtalPi’s valuation appear compressed or inconsistent depending on metric choice. Sector performance is weaker year-to-date, and AI-enabled drug discovery names face high multiple dispersion and investor selectivity.
Meyka AI grades and 2228.HK stock forecast
Meyka AI rates 2228.HK with a score out of 100: 63.14 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst views. Meyka AI’s forecast model projects a yearly price of HK$10.66, a quarterly target of HK$11.76, and a three-year view of HK$14.62. Compared to the current HK$9.91, the one-year implied upside is 7.45%. Forecasts are model-based projections and not guarantees.
Risks, catalysts and investment considerations for 2228.HK stock
Key risks include execution on AI-drug pipelines, long days sales outstanding 268.35, and high price-to-sales multiples that amplify revenue shortfalls. Catalysts include upcoming earnings announcement on 25 Mar 2026, partnership deals, and positive trial readouts. Analysts note a mixed internal rating (company rating C- on 9 Mar 2026) and advise monitoring quarter-to-quarter revenue growth and cash burn.
Final Thoughts
XtalPi (2228.HK) presents a mixed intraday picture at HK$9.91 on 10 Mar 2026. The stock shows short-term weakness with RSI 34.27 and intraday volume 25,682,300, yet balance-sheet metrics such as current ratio 9.69 and cash per share 0.92 HKD provide a buffer. Meyka AI’s model projects HK$10.66 in one year, implying 7.45% upside from today. We flag valuation mismatches: price/sales 54.35 and price/book 4.63 require revenue traction to justify multiples. For traders, a confirmed break above the 50-day average HK$11.38 would be constructive. For longer-term investors, monitor the earnings release on 25 Mar 2026, trial results, and any revenue guidance revisions. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model outputs and not investment guarantees.
FAQs
What is the current price and intraday range for 2228.HK stock?
The 2228.HK stock trades at HK$9.91 intraday on 10 Mar 2026. Today’s range is HK$9.77 to HK$10.08 with volume of 25,682,300 shares and market cap about HK$41.91B.
What price target does Meyka AI give for 2228.HK stock?
Meyka AI’s forecast model projects HK$10.66 for one year and HK$11.76 quarterly. The one-year implied upside from HK$9.91 is 7.45%. Forecasts are model-based projections and not guarantees.
What are the main valuation metrics for 2228.HK stock?
Reported EPS is 1.05 with a P/E of 9.28 and price/book 4.63. Price/sales is high at 54.35, while free cash flow per share is negative at -0.13 HKD, indicating valuation depends on future revenue growth.
When is the next earnings report for 2228.HK stock?
XtalPi has an earnings announcement scheduled for 25 Mar 2026. Investors should watch revenue trends, cash flow, and management guidance for AI-driven drug discovery progress.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)